Personalizing small-cell lung cancer treatment: subsets, chemoimmunotherapy, and future prospects
Ticiana Leal, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the heterogeneity of small-cell lung cancer (SCLC) and the requirement of a more personalized treatment approach. Extensive research has identified four subsets of SCLC based on transcription factors, including SCLC-A, SCLC-P, SCLC-I (inflamed or YAP1), and a triple-negative subset. Exploratory analysis of landmark trials, such as the Phase III IMpower133 (NCT02763579) and CASPIAN (NCT03043872) trials, suggests that patients with the SCLC-I subset may benefit more from chemoimmunotherapy, highlighting the need for prospective clinical trials in this specific population. Preclinical studies have also identified potential markers, such as DLL3, that could be targeted in certain subsets for the development of new therapies. Incorporating these subsets in future trials may lead to more personalized treatments for SCLC patients based on their unique disease characteristics. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found